PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
22-Sep-2022 Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago Relief Therapeutics Holding SA
21-Sep-2022 Medacta announces first revision surgeries in the US using the unique-on-the-market and innovative MyKnee R patient-specific solution Medacta Group SA
21-Sep-2022 Original-Research: Haemato AG (von First Berlin Equity Research GmbH) Haemato AG
21-Sep-2022 Novo Nordisk Foundation launches major investment to develop the first quantum computer dedicated to life sciences research and the green transition Novo Nordisk
21-Sep-2022 Defence Therapeutics Inc.: BREAKTHROUGH RESULTS WITH ACCUM(TM) A1-REPROGRAMMED MSC, MESENCHYMAL STEM CELLS, IN A NOVEL VACCINE CURED 80% OF ANIMALS WITH PRE-ESTABLISHED LYMPHOMA Defence Therapeutics Inc.
21-Sep-2022 Xlife Sciences strengthens sustainability activities with ESG strategy Xlife Sciences AG
20-Sep-2022 Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process Merck
20-Sep-2022 European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis UCB
20-Sep-2022 Otsuka announces EC approval of Lupkynis®▼ (voclosporin) as first oral treatment for active lupus nephritis Otsuka
20-Sep-2022 Almirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis Almirall
20-Sep-2022 APONTIS PHARMA announces cooperation to launch new Single Pill in Germany APONTIS PHARMA AG
20-Sep-2022 Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program Evotec SE
19-Sep-2022 Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costs Epigenomics AG
19-Sep-2022 DEFENCE THERAPEUTICS APPLAUDS UNITED STATES PRESIDENT BIDEN CANCER MOONSHOT INITIATIVE Defence Therapeutics Inc.
19-Sep-2022 Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab) Formycon AG
19-Sep-2022 Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test Epigenomics AG
16-Sep-2022 Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU) Evotec SE
16-Sep-2022 AEVIS VICTORIA SA – AEVS.SW – Half-year results 2022: Net profit jumps to CHF 47.2 million AEVIS VICTORIA SA
15-Sep-2022 Abivax presents first-half 2022 financial results and operations update ABIVAX
15-Sep-2022 Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis